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Abstract
Background: There are increasing reports of severe clinical cases exclusively associated with Plasmodium
vivax infections. Notably, this severity has been recently suggested to be associated with chloroquine
resistance.
Patients: Two different patients presented at the Hospital Clinic in Barcelona with P. vivax malaria
episodes. One patient had severe symptoms and the other mild symptoms. Both patients traveled through
the Brazilian Amazon (Manaus) in 2007. For both patients the current diagnosis of malaria was the first.
Two other patients with mild symptoms presented to the "Centro de Pesquisa em Medicina Tropical", also
in the Brazilian Amazon (Rondônia) in 2000.
Methods:  To exclude the possibility that the patient's severe symptoms were due to Plasmodium
falciparum, a nested PCR was performed. A magnetic method was used to purify P. vivax free of human
leukocytes. Quantitative real-time PCR was performed to compare the transcript levels of two main
transporters likely to be involved in chloroquine resistance in P. vivax, namely the P. vivax chloroquine
resistance transporter, pvcrt-o, and the P. vivax multidrug resistance transporter, pvmdr 1.
Results: Results demonstrated that the severe clinical symptoms were exclusively due to P. vivax. The
patient presented acute respiratory conditions requiring admission to the intensive care unit. The magnetic
method showed highly purified infected-reticulocytes with mature stages. In addition, it was found that
parasites obtained from the severe patient had up to 2.9-fold increase in pvmdr1 levels and up to 21.9-fold
increase in pvcrt-o levels compared to expression levels of parasites from the other patients with mild
symptoms.
Conclusion: This is the first clinical case of severe disease exclusively associated with vivax malaria in
Spain. Moreover, these findings suggest that clinical severity could be associated with increased expression
levels of parasite genes likely involved in chloroquine resistance. It is necessary to further explore the
potential of pvmdr1 and particularly pvcrt-o expression levels as molecular markers of severe disease in P.
vivax.
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Background
The renewed momentum for global malaria eradication
has highlighted the need to further studies on Plasmodium
vivax if eradication is to be achieved. Although the exact
burden of disease is still a matter of debate, it is likely that
it has been underestimated and that P. vivax is responsible
for between 100 and 300 million clinical infections each
year [1]. The emergence of worsening clinical severity and
chloroquine resistance are two major factors responsible
for this increasing burden.
Plasmodium vivax infections have been associated with
mild symptoms such as fever, headache, fatigue, chills,
and musculoskeletal pain, in particular paroxysms.
Recently, however, severe complications, including renal
failure, jaundice, acute respiratory distress syndrome, cer-
ebral malaria, seizures, anaemia, hyperparasitaemia,
thrombocytopenia, pulmonary edema, splenic rupture
and death, have been reported in exclusive association
with P. vivax [2,3].
Chloroquine resistance (CQR) is a major determinant of
the present resurgence of malaria worldwide, including
that of P. vivax [4]. Two main transporters have been stud-
ied in regard to CQR in P. vivax: the P. vivax chloroquine
resistance transporter, Pvcrt-o, and the P. vivax multidrug
resistance transporter, Pvmdr1 [5-7]. Interestingly, amino
acid polymorphisms have not been associated with chlo-
roquine resistance in pvcrt-o  whereas  pvmdr1  polymor-
phisms have been recently suggested to be associated with
CQR in Southeast Asia [8]. This data indicates the involve-
ment of other mechanisms in CQR in P. vivax. Likely can-
didates are gene amplifications and differential expression
levels [9,10].
The European Network on Imported Infectious Disease
Surveillance, TropNetEurop, is an electronic network of
clinical sites that monitors imported infectious diseases in
Europe http://www.tropnet.net. Since its foundation in
1999, the network has recorded 8,374 cases of malaria, of
which close to 11% (930) were due to P. vivax. Worth
mentioning, TropNetEurop covers approximately 10% of
all malaria cases reported in Europe. Moreover, according
to data from the Spanish National Center of Epidemiol-
ogy and the Autonomous Government of Catalonia there
have been 266 cases of P. vivax in Spain in the last six
years. In addition, three cases of severe symptoms due to
P. vivax in Europe have been reported elsewhere in the lit-
erature [11-13]. These figures illustrate the clinical-epide-
miological importance of this parasitic disease in a
supposedly malaria-free region.
Recently, CQR in P. vivax has been suggested to be associ-
ated, albeit not directly linked, with severe vivax malaria
[14]. Here, the first clinical case of severe vivax malaria in
Spain is presented. The data also indicates that clinical
severity could be associated with increased expression lev-
els of two parasite genes likely involved in chloroquine
resistance, pvmdr1 and pvcrt-o.
Methods
Subjects
Two patients presented at Hospital Clinic in Barcelona
with P. vivax malaria episodes. One had severe symptoms
and the other mild symptoms. The patients had travelled
through the Brazilian Amazon (Manaus) for 31 and 19
days, respectively, in 2007. The patient with severe symp-
toms was a 30-year-old Spaniard man who had previously
travelled to Kenya, in 2006. Upon his return from Brazil,
he presented to Hospital Clinic in Barcelona with high
fever (39°C) and a Giemsa-stained thin blood film con-
firmed the presence of P. vivax at a parasitaemia of 1.8%.
The patient presented acute respiratory conditions, anae-
mia and hyperbilirubinaemia, requiring admission to the
intensive care unit. The patient with mild symptoms was
a 31-year-old Spaniard man who had travelled without
chemoprophylaxis and who had previously visited Mex-
ico (2006), Vietnam (2005), and India (2004). There were
no records of fever episodes from these previous trips and
neither of the patients had ever been diagnosed with
malaria.
Two other Brazilian patients with mild symptoms pre-
sented at the "Centro de Pesquisa em Medicina Tropical,
Rondônia, Brazil in 2000. Total RNA from parasites of
these patients was extracted, pooled and stored in liquid
nitrogen.
Samples
Five mL of infected red blood cells were obtained from
each patient. One mL was used to purify genomic DNA
following standard methodologies. The remaining blood
was processed to isolate total RNA using the Trizol reagent
(Invitrogen) according to the manufacturers' instructions.
A recently described magnetic method for the isolation of
matures stages of malaria parasites was used to concen-
trate and purify P. vivax-infected reticulocytes [15].
Giemsa-stained smears showed an absence of human leu-
kocytes, and all the reticulocytes were infected with
mature stages of the parasite (Additional file 1). Eluents
were centrifuged at 800 × g for 10 minutes, supernatants
discarded, and pellets used to purify total RNA. The pro-
tocol for this study was approved by the Ethical Commit-
tee of Hospital Clinic and informed consent obtained
from the patients.
Nested PCR
Nested polymerase chain reaction (PCR) was performed
as previously described [16] to exclude P. falciparum infec-Malaria Journal 2009, 8:55 http://www.malariajournal.com/content/8/1/55
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tions. Fragments were resolved and visualized on 2% aga-
rose gels stained with sybr green.
qRT-PCR
Amplification reactions were performed using Power
SYBR Green PCR Master Mix (Applied Biosystems) and 45
ng of template cDNA prepared from each sample. Sam-
ples were set up in duplicate and experiments were
repeated independently twice. PCR products were ampli-
fied and detected on an ABI Prism 7700 (Applied Biosys-
tems). Cycling parameters for PCR were an initial
denaturation step at 95°C for 10 minutes, followed by 40
cycles of 95°C for 15 seconds, and 60°C for 1 minute. To
analyse the relative transcript levels, the threshold cycle
value (Ct) of each sample was used to calculate and com-
pare the ΔCt of each sample to that of the P. vivax house-
keeping gene Sal I β-tubulin; the ΔΔCt was also calculated
as in [17] to compare the transcript levels of pvcrt-o and
pvmdr 1 in the patient with severe symptoms and in the
patient with mild symptoms.
Results
Case report
During the month of August, 2007, a 30-year-old Spanish
tourist traveled through the Brazilian Amazon region of
Manaus, where, due to gastric disturbances, he took an
incomplete chemoprophylaxis consisting of proguanil
and chloroquine. Upon his return to Spain 30 days later,
he presented to a health center with an eight-day history
of fever, chills and dry cough. He was diagnosed with
lower respiratory tract infection and treated with amoxi-
cillin-clavulanic acid 875/125 mg every 8 hours for 24
hours (3 doses) without resolution. On presenting a week
later to Hospital Clinic in Barcelona, he had high fever
(39°C) and jaundice; the tip of the spleen was palpable
and chest auscultation was unremarkable. A thin blood
smear of peripheral blood stained with Giemsa revealed
P. vivax infection with a parasitaemia of 1.8%. The patient
presented acute respiratory conditions requiring admis-
sion to the intensive care unit (ICU).
In the ICU, he was haemodynamically stable and blood
tests revealed pancytopaenia (haemoglobin, 10 g/L; hae-
matocrit, 29%; platelets 25 × 109/L, leukocytes, 6.7 × 109/
L); hyperbilirubinaemia (8.3 g/dL); γ-glutamyltransferase,
146 U/L; alkaline phosphatase, 241 U/L; and pro-
thrombin time, 76 seconds. Renal function tests were
within normal limits. The C-reactive protein level was 16
mg/dL. Arterial blood gas measurement while breathing
air revealed marked hypoxia (PaO2, 63 mm Hg), normo-
capnia (PaCO2, 32 mm Hg), low oxygen saturation
(93.7%), and a blood pH of 7.49. A chest radiograph
showed bilateral interstitial infiltrates and a computed
tomography (CT) scan showed right midzone alveolar
shadowing without parenchymal infiltrations (Figures 1A
and 1B).
To exclude the possibility that the patient's severe symp-
toms were due to P. falciparum, which is sympatric with P.
vivax in Brazil, a nested PCR using P. falciparum- and P.
vivax-specific primers, was performed [16]. The results
demonstrated that coinfection with P. falciparum could be
excluded (Figure 2A). Moreover, sputum, blood, and
nasopharyngeal swab samples obtained for culture were
negative, as were serological tests for atypical respiratory
pathogens, human immunodeficiency virus, histoplasma,
coccidians, and paracoccidians. Together, these results
demonstrated that the clinical symptoms were exclusively
due to P. vivax infection.
X-ray and computed tomography (CT) scans of patient with severe Plasmodium vivax malaria Figure 1
X-ray and computed tomography (CT) scans of patient with severe Plasmodium vivax malaria. Interstitial bilateral 
infiltrates compatible with acute lung injury in X-ray (Panel A). Infiltrates in right midzone in CT scan (panel B). Normal CT 
scan two months after acute episode (panel C).
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Due to the severe condition of the patient, a five-day treat-
ment was initiated, starting with an intravenous loading
dose of quinine (1,200 mg) on the first day, followed by
oral quinine (600 mg) every 8 hours plus oral doxycycline
(100 mg) every 12 hours. The treatment was well-toler-
ated and parasitaemia became negative within three days.
Platelet, erythrocyte and leukocyte levels were all within
normal ranges in the following controls. Normal blood
levels of glucose-6-phosphate dehydrogenase activity
were detected and oral primaquine (30 mg/day) was com-
menced for two weeks to prevent a relapse. The patient
recovered well and the chest CT findings were normal at
two months (Figure 1C). There have been no recurrences
during the follow-up period.
Increased expression levels of drug resistance genes
In view of the recently suggested association of severe dis-
ease in P. vivax with multidrug resistance [14], expression
levels of two genes suspected in having a pivotal role in
mediating clinical resistance to chloroquine, pvcrt-o and
pvmdr1, were determined. Significantly, the patient with
severe symptoms had a 1.6-fold increase in pvmdr1 levels
and a 21.9-fold increase in pvcrt-o levels compared to the
other patient who presented to the same hospital with P.
vivax infection and mild symptoms (Figure 2b). This find-
ing was validated by analysing parasite material obtained
previously from two other patients from the Brazilian
Amazon who also had mild symptoms (Additional file 2).
Discussion
There are increasing reports of severe clinical cases exclu-
sively associated with P. vivax infections, involving severe
anaemia, renal failure, jaundice, cerebral malaria, sei-
zures, respiratory failure, multi-organ failure, and death
[2,3]; all these complications are generally believed to be
exclusively associated with severe forms of falciparum
malaria. Although these same clinical severity criteria are
being used for P. vivax, it would be desirable to conduct
prospective studies to establish a precise definition of clin-
ical severity in P. vivax.
Expression levels of chloroquine resistance genes in severe and mild Plasmodium vivax malaria Figure 2
Expression levels of chloroquine resistance genes in severe and mild Plasmodium vivax malaria. In panel A, nested 
PCR to identify Plasmodium species. Amplification of gDNA from P. falciparum 3D7 strain and P. vivax from severe patient, 
respectively, using specific P. vivax primers (lanes 1 and 2). Amplification of gDNA from P. falciparum 3D7 strain and P. vivax 
from severe patient, respectively, using specific P. falciparum primers (lanes 3 and 4). Molecular weight ladder (lane L). A posi-
tive reaction is noted when primers for P. falciparum and P. vivax produce amplification products of 205-bp and 120-bp, respec-
tively [16]. Molecular weight in base-pairs (bp). In panel B, relative quantification of pvcrt-o and pvmdr1 transcripts in total RNA 
obtained from parasites from the severe patient vs total RNA obtained from parasites from a patient from Brazil with P. vivax 
and non-severe symptoms also presenting to our hospital. The following oligonucleotide primers were designed for the real-
time experiments using the Primer Express program (Applied Biosystems). Primers: F-pvcrt-oRT 5'-ATGTCCAAGATGT-
GCGACGAT-3';R-pvcrt-oRT 5'-CTGGTCCCTGTATGCAACTGAC-3'; F-pvmdr1RT 5'-AAGGATCAAAGGCAACCCA-3'; R-
pvmdr1RT5'-TCAGGTTGTTACTGCTGTTGCTATT-3'; F-pvtubulinRT 5' CCAAGAATATGATGTGTGCAAGTG 3'; R-pvtu-
bulinRT 5' GGCGCAGGCGGTTAGG 3'.Malaria Journal 2009, 8:55 http://www.malariajournal.com/content/8/1/55
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The patient with severe symptoms had acute lung injury
according to the definition of the American-European
Consensus Conference on ARDS [18], with acute onset,
bilateral changes in chest radiography, a PaO2/FiO2 ratio
of ≤ 300, and absence of clinical left ventricular failure.
Importantly, these respiratory complications appeared
before initiation of anti-malarial drug treatment, an
observation also reported in two other severe clinical cases
of lung injury due to P. vivax [19,20]. Two main hypothe-
ses have been proposed to explain lung damage in P. vivax
malaria infections. The first suggests that there is no
sequestration of P. vivax-infected reticulocytes in the deep
capillaries of internal organs, postulating instead an
inflammatory process due to an increase in capillary per-
meability associated with cytokine-induced damage in the
pulmonary epithelium [21]. The second suggests cytoad-
herence of P. vivax-infected reticulocytes in lung capillar-
ies, causing obstruction of blood flow and reduction of
respiratory function before treatment and alveolar capil-
lary damage and inflammation 24 to 48 hours after initi-
ation of anti-malarial drug treatment [22]. The possibility
that antibiotics given 24 hours before respiratory failure
might have destroyed P. vivax-infected reticulocytes,
inducing lung damage and favouring the second hypoth-
esis, cannot formally rule out. Yet, it is clear that the lack
of sequestration in P. vivax needs to be re-evaluated, as
cytoadherence has been hypothesized to occur in both the
spleen [23,24] and the lungs [22].
Chloroquine is currently the first-line treatment for P.
vivax, but resistance has been rapidly increasing since it
was first described in two cases of treatment failures in
Papua New Guinea [4]. The clinical case reported here
originated in Manaus, Brazil, where P. vivax chloroquine
resistance and severe disease are now being reported
[25,26]. Interestingly, after the appearance of chloroquine
resistance in P. vivax, reports of clinical severity exclusively
associated with this human malaria parasite started to
appear [2]. Moreover, multidrug resistance has been
recently suggested to be associated, albeit  not directly
linked, with severe disease in P. vivax [14]. Remarkably,
higher expression levels of pvmdr1 and pvcrt-o, in particu-
lar, were found in parasites from the patient with severe
clinical symptoms compared to three patients with mild
symptoms. The levels were increased by up to 2.9 fold in
the case of pvmdr1 (when including all samples) and up to
21.9 fold in the case of pvcrt-o. Confounding effects due to
sample concentrations or contamination with P. falci-
parum or human material were excluded by using P. vivax-
specific primers and β-tubulin as an internal control and
calibrator. This data thus indicates that severe vivax dis-
ease could be associated to molecular markers.
Conclusion
There are increasing reports of severe disease exclusively
associated with vivax malaria and this study presents the
first one in Spain. The use of PCR excluded incompetent
microscopy, cryptic mixed infections or sequestered P. fal-
ciparum reinforcing the need of using PCR as a new diag-
nostic tool to avoid default diagnosis of severe malaria as
due to P. falciparum. The finding on increased expression
levels of parasite genes likely involved in chloroquine
resistance supports to furthering explore the potential of
pvmdr1 and particularly pvcrt-o as molecular markers of
severe disease in P. vivax.
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